Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA: Telbivudine vs Tenofovir in HBeAg-negative Chronic Hepatitis B
NCT01379508Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2011
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 8
01
Overview
Phase 4, randomised, open-label trial of telbivudine in Chronic Hepatitis B (CHB) (2 arms), sponsored by Novartis. Primary endpoint: Percentage of Participants Achieving HBV DNA < 300 Copies/mL (51 IU/mL) at 52 weeks. Started Mar 2011; status: completed.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01379508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01379508.